Cargando…

Successful treatment of disseminated intravascular coagulation by recombinant human soluble thrombomodulin in patients with acute myeloid leukemia

Disseminated intravascular coagulation (DIC) is a life-threatening condition that frequently occurs in patients with hematologic malignancies. Currently, recombinant human soluble thrombomodulin (rTM) is a therapeutic DIC drug that is manufactured and sold in Japan only. We evaluated the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ookura, Miyuki, Hosono, Naoko, Tasaki, Toshiki, Oiwa, Kana, Fujita, Kei, Ito, Kazuhiro, Lee, Shin, Matsuda, Yasufumi, Morita, Mihoko, Tai, Katsunori, Negoro, Eiju, Kishi, Shinji, Iwasaki, Hiromichi, Ueda, Takanori, Yamauchi, Takahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221668/ https://www.ncbi.nlm.nih.gov/pubmed/30383650 http://dx.doi.org/10.1097/MD.0000000000012981

Ejemplares similares

Successful Administration of Recombinant Human Soluble Thrombomodulin α (Recomodulin) for Disseminated Intravascular Coagulation during Induction Chemotherapy in an Elderly Patient with Acute Monoblastic Leukemia Involving the t(9;11)(p22;q23) MLL/AF9 Translocation
por: Takagi, Kazutaka, et al.
Publicado: (2011)

3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis
por: Araie, Hiroaki, et al.
Publicado: (2017)

Prognostic effect of peripheral blood cell counts in advanced diffuse large B-cell lymphoma treated with R-CHOP-like chemotherapy: A single institution analysis
por: YAMAUCHI, TAKAHIRO, et al.
Publicado: (2015)

Efficacy of recombinant human soluble thrombomodulin in disseminated intravascular coagulation
por: Yasuda, T, et al.
Publicado: (2010)

Clinical Impact of Recombinant Soluble Thrombomodulin for Disseminated Intravascular Coagulation Associated with Severe Acute Cholangitis
por: Okuda, Atsushi, et al.
Publicado: (2018)

Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome
por: TAKAI, MIHOKO, et al.
Publicado: (2014)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
por: Nishi, Rie, et al.
Publicado: (2020)

Efficacy of Combined Thrombomodulin and Antithrombin in Anticoagulant Therapy for Acute Cholangitis-induced Disseminated Intravascular Coagulation
por: Morita, Nozomi, et al.
Publicado: (2018)

Adequate application of recombinant thrombomodulin for sepsis-associated disseminated intravascular coagulation
por: Iba, Toshiaki
Publicado: (2015)

Thrombomodulin/activated protein C system in septic disseminated intravascular coagulation
por: Ikezoe, Takayuki
Publicado: (2015)

Management of disseminated intravascular coagulation: current insights on antithrombin and thrombomodulin treatments
por: Hayakawa, Mineji
Publicado: (2017)

Effect of Thrombomodulin Alfa on Disseminated Intravascular Coagulation in Patients with Lung Cancer
por: Nakano, Kentaro, et al.
Publicado: (2017)

Factors influencing the effectiveness of recombinant human soluble thrombomodulin on disseminated intravascular coagulation: a retrospective study
por: Asai, Yuki, et al.
Publicado: (2020)

Use of Antithrombin and Thrombomodulin in the Management of Disseminated Intravascular Coagulation in Patients with Acute Cholangitis
por: Nakahara, Kazunari, et al.
Publicado: (2013)

TAFRO Syndrome with Disseminated Intravascular Coagulation Successfully Treated with Tocilizumab and Recombinant Thrombomodulin
por: Takayama, Yusuke, et al.
Publicado: (2017)

Clinical efficacy of recombinant human soluble thrombomodulin in patients with septic disseminated intravascular coagulation
por: Suzuki, Y, et al.
Publicado: (2013)

Effects of combination therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation
por: Iba, Toshiaki, et al.
Publicado: (2017)

YM155 exerts potent cytotoxic activity against quiescent (G(0)/G(1)) multiple myeloma and bortezomib resistant cells via inhibition of survivin and Mcl-1
por: Ookura, Miyuki, et al.
Publicado: (2017)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

Thrombomodulin phenotype of a distinct monocyte subtype is an independent prognostic marker for disseminated intravascular coagulation
por: Hwang, Sang Mee, et al.
Publicado: (2011)

The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study
por: Yoshihara, Masato, et al.
Publicado: (2015)

Pharmacokinetics of Recombinant Human Soluble Thrombomodulin in Disseminated Intravascular Coagulation Patients with Acute Renal Dysfunction
por: Hayakawa, Mineji, et al.
Publicado: (2017)

Prognostic value of metabolic tumor volume of extranodal involvement in diffuse large B cell lymphoma
por: Oiwa, Kana, et al.
Publicado: (2023)

The Relative Dose Intensity Changes during Cycles of Standard Regimens in Patients with Diffuse Large B-Cell Lymphoma
por: Lee, Shin, et al.
Publicado: (2023)

Prognostic factors in patients with septic disseminated intravascular coagulation treated with thrombomodulin: the effect of reduced thrombomodulin dose; a single-center, retrospective, observational study
por: Nishita, Yoshihiro, et al.
Publicado: (2022)

Benefit Profile of Thrombomodulin Alfa Combined with Antithrombin Concentrate in Patients with Sepsis-Induced Disseminated Intravascular Coagulation
por: Murao, Atsushi, et al.
Publicado: (2022)

Thrombomodulin as a Physiological Modulator of Intravascular Injury
por: Watanabe-Kusunoki, Kanako, et al.
Publicado: (2020)

Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis
por: Yamakawa, Kazuma, et al.
Publicado: (2013)

Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation
por: Eguchi, Yutaka, et al.
Publicado: (2014)

Use of Recombinant Human Soluble Thrombomodulin in Patients with Sepsis-Induced Disseminated Intravascular Coagulation after Intestinal Perforation
por: Tagami, Takashi, et al.
Publicado: (2015)

Thrombomodulin in disseminated intravascular coagulation and other critical conditions—a multi-faceted anticoagulant protein with therapeutic potential
por: Ito, Takashi, et al.
Publicado: (2019)

Effectiveness of combined antithrombin and thrombomodulin therapy on in-hospital mortality in mechanically ventilated septic patients with disseminated intravascular coagulation
por: Umegaki, Takeshi, et al.
Publicado: (2020)

Effect of Recombinant Human Soluble Thrombomodulin on Coagulation-Related Variables in Patients With Sepsis-Induced Disseminated Intravascular Coagulation: A Retrospective Observational Study
por: Mitaka, Chieko, et al.
Publicado: (2021)

Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors
por: Ouchi, Kota, et al.
Publicado: (2018)

Successful Control of Disseminated Intravascular Coagulation by Recombinant Thrombomodulin during Arsenic Trioxide Treatment in Relapsed Patient with Acute Promyelocytic Leukemia
por: Shindo, Motohiro, et al.
Publicado: (2012)

Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis
por: Yoshimura, Jumpei, et al.
Publicado: (2015)

Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study
por: Kato, Takahiro, et al.
Publicado: (2013)

Recombinant Thrombomodulin Used to Successfully Treat Cronkhite-Canada Syndrome with Disseminated Intravascular Coagulation due to Sepsis in a Compromised Patient
por: Morino, Kahori, et al.
Publicado: (2018)

Concomitant Versus Individual Administration of Antithrombin and Thrombomodulin for Sepsis-Induced Disseminated Intravascular Coagulation: A Nationwide Japanese Registry Study
por: Umemura, Yutaka, et al.
Publicado: (2018)

Pharmacokinetics of Standard- and Reduced-Dose Recombinant Human Soluble Thrombomodulin in Patients with Septic Disseminated Intravascular Coagulation during Continuous Hemodiafiltration
por: Watanabe, Eizo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_af7r2ue8pl8omp91osl5gfsg7m